Exploring Oral Systemic Therapies for Plaque Psoriasis: Efficacy, Safety, and Clinical Considerations

Lauren Miller, MPAS, PA-C; Jayme M. Heim, MSN FNP-BC, and Kirk Gautier, PA-C, discuss recent advancements in plaque psoriasis treatment, focusing on novel oral systemic therapies like the TYK-2 inhibitor deucravacitinib and its clinical trial data, to inform therapeutic decisions for this systemic disease.

Related Content:

ClinicalMedcast PodcastsVideo Series

Multi-Stakeholder Collaboration Makes 2024 a Landmark Year for Biosimilars

Sleep Medicine Year in Review: 2024

Crisis Point: Benzene Concerns in Acne Care